

**Session Title:** #13: Application of Epigenetics to Diagnosis and Therapy

**Session Type:** Education Session

**Date:** Friday, June 4

**Location:** S406 (Vista Room)

**Time:** 2:45 PM - 4:00 PM

- Cancer Epigenetics- Basic Biology  
*Gerd P Pfeifer, PhD*
  - Can we use epigenetics in early detection of cancer?  
*Paul Cairns, PhD*
  - Use of epigenetic information for individualized cancer care  
*Jean Pierre Issa, MD*
- 

**Session Title:** #213: Tumor Biology

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

40A #10538-EGFR mutations in men and cigarette smokers with lung adenocarcinoma.

*Maria Catherine Pietanza*

40B #10539-Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial.

*Eva Johanna Kantelhardt*

40F #10540-Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial.

*John D. Hainsworth*

40G #10541-Effect of IKK&epsilon; knock-down on prostate cancer xenograft growth.

*Benjamin Péant, PhD*

40H #10542-Immunohistochemistry detection of epidermal growth factor receptor (EGFR) exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using novel mutation specific antibodies.

*Yasufumi Kato, MD, PhD*

41A #10543-Analysis of the methylation profile of 49 cancer-related regions in human breast cancer.

*Diego Matias Marzese*

41B #10544-Prospective multicentric trial evaluating prognostic and predictive value of circulating tumor cells in first-line chemotherapy metastatic breast patients.

*Jean-Yves Pierga*

41C #10545-Effect of kinesins on taxane resistance.

*Robert Wesolowski*

41D #10546-Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03.

*Susanna J. Jacobus*

41E #10547-Early operable primary breast cancer in elderly (>= 70 years) women: Are they biologically different from their younger counterparts?

*Kwok-Leung Cheung*

41F #10548-Can cetuximab specific IgE antibodies predict cetuximab-induced anaphylaxis?

*Benoît Dupont*

41G #10549-Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy.

*Allen M. Gown, MD*

41H #10550-Identification of DNA methylation changes in esophageal cancer before/after chemoradiation therapy using a MCA-microarray and bisulfate pyrosequencing.

*Takashi Tsuda*

42A #10551-Prediction of response to neoadjuvant therapy in breast cancer using plasma and tumor proteomic analyses.

*Christophe Desauw*

42B #10552-Value of quantitative DNA fingerprinting in classification of second breast tumors and association with outcome.

*Benjamin L Schlechter*

42C #10553-CpG-b oligodeoxynucleotides potently activate human NK cells and sensitize chronic lymphocytic leukemia cells to NK cell-mediated killing.

*Veronika Bachanova*

42D #10554-Use of a combination of 5-fluorouracil pathway genes to predict treatment outcome of S-1 monotherapy in advanced gastric cancer.

*Gun Min Kim*

42E #10555-Use of CD8 and Foxp3 immune infiltrates after neoadjuvant chemotherapy to predict survival in HER2-overexpressing breast cancer patients.

*François Ghiringhelli*

42F #10556-Efficient detection of *EGFR* alterations in lung adenocarcinomas.

*Marc G Denis*

42G #10557-Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib.

*Jingxun Wu*

42H #10558-Biomarkers of early operable primary breast cancer in elderly (>= 70 years) women (EPC) and their correlation with breast cancer-specific survival (BCSS).

*Binafsha Manzoor Syed, MBBS*

43A #10559-Clinical significance of 18F-alpha-methyl tyrosine PET as a potential surrogate marker of LAT1 expression for predicting prognosis of non-small cell lung cancer.

*Noboru Oriuchi*

43B #10560-Correlation of expression of circadian genes with liver metastasis and outcomes in colorectal cancer.

*Takashi Oshima, MD, PhD*

43C #10561-Epigenetic silencing of Dab-2 in head and neck cancer.

*Cristiana Lo Nigro, Ph.D., D.Sc.*

43D #10562-The single-nucleotide polymorphism A>G rs397768 in APC gene as a new biomarker of response to chemotherapy in advanced colorectal cancer.

*José Carlos Villa Guzman*

43E #10563-Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM).

*Priti Hegde*

43F #10564-Use of peripheral blood mRNA signatures to distinguish colorectal cancer patients from colonoscopy-negative patients.

*Ye Xu*

43H #10566-Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC).

*Riet Hilhorst*

44A #10567-Prognostic value of serum protein biomarkers in patients with epithelial ovarian cancer.

*Meiyao Wang*

44B #10568-Relationship of expression level of CD133 with tumor angiogenesis and prognosis of hepatocellular carcinoma after liver transplantation.

*Yang Xu*

44C #10569-Lung cancer autoantibody signature as indicator of early disease.

*Tetyana V. Pedchenko*

44D #10570-Evaluation of the prognostic value of UBE2C mRNA levels in early breast cancer.

*Diamando Psyrrri*

44E #10571-Use of T-cell proliferation to predict survival and recurrence in patients with resected colorectal liver metastases.

*Ajay V Maker*

44F #10572-Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy.

*Stephen R. D. Johnston*

44G #10573-Markers of anaerobic glycolysis as predictive factor in neoadjuvant chemoradiotherapy of rectal cancer.

*Der Sheng Sun*

44H #10574-SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and *nab*-paclitaxel (*nab*-P) in locally advanced breast cancer (LABC).

*Denise Aysel Yardley*

45A #10575-Gene expression differences in current versus former smokers lung squamous preneoplasia.

*Celine Joselyne Monique Mascaux*

45B #10576-Molecular profiling of pulmonary pleomorphic carcinoma: Implications for targeted treatment of a rare lung malignancy.

*Youngwook Kim*

45C #10577-Role of the type III TGF- $\beta$  receptor in mediating immunosuppression during breast cancer progression.

*Brent Allen Hanks*

45D #10578-Use of circulating and tumor-infiltrating myelomonocytic cells to predict survival in human malignant pleural mesothelioma (MPM).

*Bryan Burt*

45E #10579-Impact of a gene expression-based tissue of origin test on diagnosis and recommendations for first-line chemotherapy.

*Marianne Laouri*

45F #10580-Circulating exosomes may provide a more sensitive platform to monitor disease progression compared to circulating tumor cells.

*Traci L Pawlowski, PhD*

45G #10581-Use of peripheral blood mRNA signature to distinguish patients with breast cancer from benign breast disease and nonconclusive mammography.

*BenLong Yang*

45H #10582-Predictive value of the Theros Breast Cancer Index (TBCI) for distant recurrence and overall survival (OS) in comparison to Adjuvant! Online and clinicopathologic characteristics in women with lymph node (LN)-negative, ER-positive breast cancer (BCa).

*Rachel Catherine Jankowitz*

46A #10583-MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma.

*David Easty*

46B #10584-Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC).

*Andrzej Badzio*

46C #10585-Evaluation of macrophage inflammatory protein-3 alpha (MIP-3a) as a serum marker for prognosis of colorectal cancer.

*Takashi Iwata*

46D #10586-Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients.

*Pedro Mendez*

46E #10587-D-dimer levels and prediction of overall survival in cancer patients.

*Cihan Ay, MD*

46F #10588-The prognostic relevance of CXC-chemokines in stage II and III colorectal cancer (CRC) tissue and inflammatory infiltrate.

*Olabode Oladipo*

46G #10589-Relations of circadian clocks genes with endocrine, proliferation, differentiation, and P53 mutation status in human locally invasive primary breast cancer.

*Ida Iurisci*

46H #10590-Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer.

*Keith A. Dookeran, MD, MBA*

47A #10591-Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and -negative oropharyngeal squamous cell carcinoma (OSCC).

*Federica Perrone*

47B #10592-Implication of the alternative NF-kappa B pathway in prostate cancer progression.

*Ingrid Labouba*

47C #10593-Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB).

*Emily Gustava Lipsitz*

47D #10594-Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors.

*Angela Zupa*

47E #10595-Nuclear expression of aryl hydrocarbon receptor and prognosis for non-small lung cancer.

*Han Chang, MD, PhD*

47F #10596-Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy.

*Kathy Mason*

47G #10597-Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer.

*May Abdel-Wahab, MD, PhD*

47H #10598-Clinico-pathologic features of lung cancer with EML4-ALK translocation.

*Tetsuya Mitsudomi*

48A #10599-Evaluation of ADAM28 as a serological and histochemical marker for non-small cell lung cancers.

*Hiroaki Kuroda*

48B #10600-Effect of plasma SPARC on outcome in cancer models.

*Neil Desai*

48C #10601-Evaluation of the hedgehog pathway as a therapeutic target for preventing the progress to invasive-stage from noninvasive-stage breast cancer.

*Masae Sozaki, MD*

48D #10602-Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment.

*Nicola Normanno*

48E #10603-Clinical relevance of the detection of tumor cells in the bone marrow of patients before lung cancer surgery.

*Rie Nakahara*

48F #10604-Molecular markers for epithelial-mesenchymal transition (EMT) and tumor aggressiveness in breast carcinoma.

*Seema Sethi*

48G #10605-Risk partitioning model shows need to address time dependence of breast cancer recurrence.

*Laura Esserman*

48H #10606-Role and prognostic value of placenta growth factor (PlGF) in colorectal carcinomas.

*Moo Jun Baek*

49A #10607-Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer.

*Inke Luehr*

49B #10608-BRCA1 expression evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in operable breast cancer.

*Piotr Potemski*

49C #10609-Gene set comparison analyses of gene expression signatures for the acquired chemotherapy resistance.

*Hark K. Kim*

49D #10610-Activation of the PI3K pathway and prognostic information in epithelial ovarian cancer.

*Despina Debbie Handolias*

49E #10611-Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC).

*Ignacio Gil-Bazo*

49F #10612-Comparison of folate derivate levels in mucosa and tumor tissue in the course of antifolate treatment with pemetrexed.

*Bengt Gustavsson*

49G #10613-Involvement of angiogenesis genes in pathologic response of advanced ovarian carcinoma.

*Marta Mendiola*

49H #10614-Tumor characteristics and patient outcomes in ductal compared with lobular carcinoma.

*Samah Nour*

50A #10615-Substratification of 70-gene high-risk breast cancers with a validated 80-gene molecular subtyping profile.

*Femke de Snoo*

50B #10616-Prognostic significance of immunoglobulin kappa C in node-negative breast cancer is both conserved across and independent from molecular subtypes.

*Marcus Schmidt*

50C #10617-C-src: A potential target for the treatment of triple-negative breast cancer.

*Siun Walsh*

50D #10618-Cancers involving the lung mediate human marrow cell phenotype change.

*Peter J. Quesenberry*

50E #10619-Metabotropic glutamate receptor-1: A new molecular target for the therapy of triple-negative breast cancer.

*David H. Gorski*

50F #10620-Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study.

*Giuseppina Improta*

50G #10621-Triple negative breast cancers: Biomarkers and outcomes.

*Luca Malorni*

50H #10622-Effect of matrix metalloproteinase-2 on the ability of human dendritic cells to prime inflammatory TH2 cells via an IL-12 and OX40L dependent pathway.

*Emmanuelle Godefroy*

51A #10623-Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC.

*Elena Sanmartin*

51B #10624-Use of quantum dots-based immunofluorescence nanotechnology for quantitative HER2 and ER detection in breast cancer tissue array to identify correlations in HER2-overexpressed and ER-positive breast cancer.

*Chuang Chen*

51D #10626-Toll-like receptor (TLR) 7 and TLR8 expression in CD133+ cells in colorectal cancer and role for inflammation-induced TLRs in tumorigenesis and tumor progression.

*Martin Gasser*

51E #10627-Detection of aberrant *SHP-1* promoter methylation, an implication in advanced non-small cell lung cancer.

*Chanida Vinayanuwattikun*

51F #10628-Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells.

*Camille Grandclement*

51G #10629-EMMPRIN up-regulates VEGFR-2 through HIF-2alpha mediated mechanism: Consequences on angiogenesis and tumor progression.

*Faten Bougatef*

51H #10630-Evaluation of the combined expression of chemokine SDF-1 $\alpha$ ; and its receptor CXCR4 as a marker for prognosis in gastric cancer.

*Hyo Jin Lee*

52A #10631-Evaluation of CYP24A1 mRNA expression as a prognostic marker and predictor of calcitriol activity in lung adenocarcinoma.

*Nithya Ramnath, MD*

52B #10632-Integrated genomics-based discovery of new oncoproteins as a biomarker and a molecular target for lung cancer.

*Yataro Daigo*

52C #10633-Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens.

*April K. Salama, MD*

52D #10634-DNA repair biomarker alterations in breast cancer relevant to adjuvant chemotherapy treatment decisions.

*Kam M Sprott*

52E #10635-MicroRNAs as a potential prognostic factor in gastric cancer.

*Ofer Purim*

52F #10636-Use of immunohistochemical profiling of node-negative breast carcinomas for prediction of metastatic risk.

*Colette Charpin*

52G #10637-Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization.

*Alexei Morozov*

52H #10638-Circulating tumor cells: Multimarker gene profile for tailoring chemotherapeutic response in adeno carcinomas.

*Nikos Fersis*

53A #10639-MMP-7 serum levels as predictor or prognostic of cetuximab benefit in the treatment of advanced colorectal cancer: Results from a HCB-05 prospective trial.

*Gemma Carrera*

53B #10640-HIF-1 $\alpha$ ; and EGFR as prognostic factors for therapy response and 1-year locoregional recurrence not for distant metastasis and 2-year OS in unresectable stage IIIA NSCLC treated with combined chemoradiotherapy.

*Yanqin Yang*

53F #10641-Correlations of mRNA expression levels of genes in the targeted pathways and Kras mutation status in patients with colorectal cancer.

*Dongyun Yang*

53G #10642-Prediction of survival in early stage non-small cell lung cancer based on kinase activity profiles.

*Rob Ruijtenbeek*

53H #10643-Analysis of the prognostic role of regulatory T-lymphocyte-associated marker expression in resectable NSCLC.

*Marta Usó*

54A #10644-Role of antiapoptotic STAT3 and BCL-2 signaling in promoting lung tumor cells to survive against combined MET-/EGFR-targeted inhibitors.

*Patrick C. Ma, MD, MSc*

54B #10645-Pregnancy-associated breast cancer: Characterization and potential chemoprevention with anti-inflammatory treatment.

*Virginia F. Borges*

54F #10646-Correlation of PITX2 gene expression and invasive potential of breast cancer cells.

*Rebecca Aft, MD, PhD, FACS*

54G #10647-Correlation of the Oncotype DX recurrence score with a composite index comprised of ER, PR, HER2, and breast tumor grade.

*Joseph Geradts*

---

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

---

**Session Title:** #192: Tumor Biology

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S103

**Time:** 2:00 PM - 6:00 PM

- Tumor Biology

*Vered Stearns, MD*

- Tumor Biology

*Charles D. Lopez, MD, PhD*

1 #10513-Utilization of genomic signatures for chemotherapy response in prospective clinical studies.

*William Barry*

2 #10514-Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer.

*Silvia Darb-Esfahani*

3 #10515-Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy.

*Mark Jesus M Magbanua*

4 #10516-Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

*Christian F. Singer*

5 #10517-Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC.

*Tom John*

6 #10518-Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.

*Charlotte Elberling Almasi*

7 #10519-Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.

*Coen Bernaards*

8 #10520-Value of a serum proteomic signature in the non-invasive evaluation of lung nodules.

*Chad Victor Pecot*

9 #10521-Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules.

*Nir Peled, MD, PhD*

- Discussion

*Gerold Bepler, MD, PhD*

10 #10522-Association of TS and ERCC1 mRNA expressions with overall survival in patients enrolled in CONFIRM 1 + 2.

*Peter P Grimminger*

11 #10523-Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer.

*Maria T. Baquero*

12 #10524-Association of GRP78 gene polymorphism rs391957 with tumor recurrence in gastric and colon cancer patients.

*Pierre Olivier Bohanes, MD*

13 #10525-Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC).

*Sao Jiralerspong, MD, PhD*

14 #10526-MicroRNA deregulation in peripheral nerve sheath tumor progression.

*Nadege Presneau*

15 #10527-Chemobiological screening for identification of molecular targets for thymic epithelial cancers.

*Oscar D. Cano*

16 #10528-Molecular classification of non-small cell lung cancer using a four protein quantitative assay.

*Valsamo K. Anagnostou, MD*

17 #10529-KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy.

*Kathleen D Danenberg*

18 #10530-Prognostic implications of mutations in the epidermal growth factor receptor (*EGFR*) and *KRAS* among never-smokers with adenocarcinoma of the lung.

*Paul K. Paik*

- Discussion

*David Paul Carbone, MD, PhD*

19 #10531-Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent series of tissue microarray.

*Jin-Soo Kim, MD*

20 #10532-Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer.

*Keita Kudo*

21 #10533-ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).

*Marileila Varella-Garcia*

22 #10534-A Japanese, nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004.

*Manabu Soda*

23 #10535-A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.

*Peter V Danenberg*

24 #10536-Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.

*Victoria Rimkunas*

25 #10537-ALK chromosomal alterations in colon cancer patients.

*Clara Montagut*

- Discussion

*Robert Arthur Kratzke, MD*

---

**Session Title:** #259: Tumor Biology

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S100a

**Time:** 5:00 PM - 6:00 PM

- Tumor Biology

*Vered Stearns, MD*

- Tumor Biology

*Charles D. Lopez, MD, PhD*

1 #10513-Utilization of genomic signatures for chemotherapy response in prospective clinical studies.

*William Barry*

2 #10514-Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer.

*Silvia Darb-Esfahani*

3 #10515-Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy.

*Mark Jesus M Magbanua*

4 #10516-Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

*Christian F. Singer*

5 #10517-Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC.

*Tom John*

6 #10518-Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.

*Charlotte Elberling Almasi*

7 #10519-Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.

*Coen Bernaards*

8 #10520-Value of a serum proteomic signature in the non-invasive evaluation of lung nodules.

*Chad Victor Pecot*

9 #10521-Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules.

*Nir Peled, MD, PhD*

- Discussion

*Gerold Bepler, MD, PhD*

10 #10522-Association of TS and ERCC1 mRNA expressions with overall survival in patients enrolled in CONFIRM 1 + 2.

*Peter P Grimminger*

11 #10523-Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer.

*Maria T. Baquero*

12 #10524-Association of GRP78 gene polymorphism rs391957 with tumor recurrence in gastric and colon cancer patients.

*Pierre Olivier Bohanes, MD*

13 #10525-Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC).

*Sao Jiralerspong, MD, PhD*

14 #10526-MicroRNA deregulation in peripheral nerve sheath tumor progression.

*Nadege Presneau*

15 #10527-Chemobiological screening for identification of molecular targets for thymic epithelial cancers.

*Oscar D. Cano*

16 #10528-Molecular classification of non-small cell lung cancer using a four protein quantitative assay.

*Valsamo K. Anagnostou, MD*

17 #10529-KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy.

*Kathleen D Danenberg*

18 #10530-Prognostic implications of mutations in the epidermal growth factor receptor (*EGFR*) and *KRAS* among never-smokers with adenocarcinoma of the lung.

*Paul K. Paik*

- Discussion

*David Paul Carbone, MD, PhD*

19 #10531-Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent series of tissue microarray.

*Jin-Soo Kim, MD*

20 #10532-Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer.

*Keita Kudo*

21 #10533-ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).

*Marileila Varella-Garcia*

22 #10534-A Japanese, nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004.

*Manabu Soda*

23 #10535-A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.

*Peter V Danenberg*

24 #10536-Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.

*Victoria Rimkunas*

25 #10537-ALK chromosomal alterations in colon cancer patients.

*Clara Montagut*

- Discussion

*Robert Arthur Kratzke, MD*

---

**Session Title:** #167: Highlights of the Day I including Clinical Trials Participation Awards

**Session Type:** Highlights of the Day

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

*Everett E. Vokes, MD*

- Clinical Trials Participation Awards

*Douglas W. Blayney, MD*

- Discussion: Lymphoma and Plasma Cell Disorders

*Bruce D. Cheson, MD*

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

*Alan B Sandler, MD*

- Discussion: Patient and Survivor Care

*Gretchen Genevieve Kimmick, MD*

- Discussion: Melanoma/Skin Cancers

*F. Stephen Hodi, MD*

---

**Session Title:** #86: PARP Inhibitors and More in DNA Repair

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** E353

**Time:** 8:00 AM - 9:15 AM

- DNA Repair - Nuts & Bolts

*James M. Ford, MD*

- PARP inhibitors' function and opportunities for combination therapy

*Nicola J Curtin, PhD*

- DNA repair defect in BRCA mutant cells- a new therapeutic road

*Thomas Helleday, PhD*

---

**Session Title:** #143: Plenary Session including Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

*Douglas W. Blayney, MD*

- Plenary Session including Science of Oncology Award and Lecture

*Daniel F. Hayes, MD*

- Plenary Session including Science of Oncology Award and Lecture

*Frank McCormick, PhD, FRS*

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

*Robert A Burger*

- Discussion

*Elizabeth A. Eisenhauer, MD*

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

*Elisabeth A. Quoix*

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

*Yung-Jue Bang*

- Discussion

*Martin J. Edelman, MD*

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

*Steven O'Day, MD*

- Discussion: Ipilimumab: The light at the end of the tunnel?

*Vernon K Sondak, MD*

---

**Session Title:** #80: New Technology in Cancer Immune Therapy

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** E353

**Time:** 4:45 PM - 6:00 PM

- Chimeric Immunoreceptor Engineered T-cells

*Michel Sadelain, MD, PhD*

- T cell engineering for adoptive immunotherapy

*Zelig Eshhar, PhD*

- Combinatorial immunotherapy

*Leisha A. Emens, MD, PhD*

---

**Session Title:** #94: Stem Cells in Neuro-oncology

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** S100b

**Time:** 4:45 PM - 6:00 PM

- Stem Cells in Neuro-Oncology: overview

*Richard Gilbertson, MD, PhD*

- CNS Stem Cells as Therapeutic Targets

*Charles D. Stiles, PhD*

- Using Stem Cells to Treat Brain Tumors

*Evan Snyder, MD, PhD*

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award  
*Kim Allyson Margolin, MD*
- Highlights of the Day II including Partners in Progress Award  
*Douglas W. Blayney, MD*
- Partners in Progress Award Recipient  
*Ellen V. Sigal, PhD*
- Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
- Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
- Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
- Discussion: Myeloma  
*Jean L. Harousseau, MD*
- Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*

**Session Title:** #16: Biomarker-driven Treatment in Stage II Colon Cancer: When to Hold and When to Fold

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- Overview of adjuvant clinical trials in stage II colon cancer - results, challenges, and confusion  
*Al Bowen Benson, III, MD*
- Prognostic and predictive molecular biomarkers in stage II colon cancer - current evidence and future perspective  
*Sabine Tejpar, MD, PhD*
- Biomarker driven treatment decisions in stage II colon cancer - making

**Session Title:** #54: Health Disparities in Lung Cancer: Race, Sex, and Genes

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 8:00 AM - 9:15 AM

- Molecular Epidemiology of Lung Cancer: Ancestry Matters  
*Alex A. Adjei, MD, PhD*
- Molecular Genetic Variations Between Human Populations  
*Patrick C. Ma, MD, MSc*
- Impact of Gender on Incidence, Behavior, and Therapy of Lung Cancer

*Nithya Ramnath, MD*

**Session Title:** #97: The Biology and Treatment of Wilms Tumor

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S504

**Time:** 8:00 AM - 9:15 AM

- Wilms Tumor: Unsettled questions and controversies  
*Jeffrey Dome, MD*
- New developments in Wilm tumor genetics  
*Nazneen Rahman, PhD, FRCP*
- Gene Expression Arrays: What have they taught us about Wilms tumor?

*Elizabeth Perlman, MD*

**Session Title:** #57: Immunoconjugates as Cancer Therapeutics

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** S100b

**Time:** 1:15 PM - 2:30 PM

- The history and evolution of immunoconjugate treatment as anti- cancer therapy

*Andrew Antony Raubitschek, MD*

- The present state of trials using immunoconjugates targeting lymphoma and heme malignancies and new strategies emerging from the lab.

*Paul A. Hamlin, MD*

---

**Session Title:** #227: Unraveling the Cancer Genome: Clinical Implications of Next-Generation Technologies

**Session Type:** Clinical Science Symposium

**Date:** Monday, June 7

**Location:** S100a

**Time:** 1:15 PM - 2:45 PM

- Unraveling the Cancer Genome: Clinical Implications of Next-Generation Technologies

*Anil Potti, MD*

- #10500-Massive parallel sequencing of an African-American basal-like breast cancer: Comparison of primary tumor, metastasis, and xenograft.

*Elaine Mardis*

- #10501-Characterization of the microRNAome in a patient with acute myeloid leukemia.

*Giridharan Ramsingh*

- Discussion

*Samuel Aparicio, BM BCh, PHD, MRCPATH*

- #10502-Detection of phosphoinositide-3-kinase, catalytic, and alpha polypeptide (PIK3CA) mutations in matched tissue and plasma samples from patients with metastatic breast cancer.

*Philipp Angenendt, PhD*

- #10503-Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.

*Carol Beadling*

- Discussion

*Matthew James Ellis, PhD, MB, BCh*

---

**Session Title:** #170: Tumor Biology

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** S100a

**Time:** 3:00 PM - 6:00 PM

- Tumor Biology

*Jorge Reis-Filho, MD, PhD*

- Tumor Biology

*Robert Arthur Kratzke, MD*

- #10504-Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors.

*Shiaowen David Hsu, MD, PhD*

- #10505-Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer.

*Ekkehard Schütz*

- #10506-Use of integrated genomic analysis to evaluate BRCA-associated protein 1 (BAP1) as a mutated gene in malignant pleural mesothelioma (MPM).

*Matthew J Bott, Bsc, MD*

- #10507-Characterizing the clinical relevance of epithelial mesenchymal transition (EMT) in human tumors.

*Kristin A Higgins*

- Discussion

*David N. Hayes*

- #10508-Pre-existence of invasive cells in breast ductal carcinoma in situ.

*Virginia A. Espina*

- #10509-Relationship of breast cancer stem cells (CSCs) and chronic O<sub>2</sub>/glucose deprivation (C-OGD).

*Miguel Quintela-Fandino*

- Discussion

*Sridhar Ramaswamy, MD*

- #10510-Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers.

*Tatyana A Grushko*

- #10511-PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy.

*Sibylle Loibl*

- #10512-Protein signal pathway mapping of human breast cancer from I-SPY: Correlations with response and genomic subtyping.

*Julia Dianne Wulfschlegel*

**Session Title:** #169: Highlights of the Day III

**Session Type:** Highlights of the Day

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day III  
*Kathy Miller, MD*
- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy  
*Kathy Miller, MD*
- Discussion: Lung Cancer - Metastatic  
*Charles M. Rudin, MD, PhD*
- Discussion: Sarcoma  
*Gary K. Schwartz, MD*
- Discussion: Gastrointestinal (Noncolorectal) Cancer  
*C. D. Blanke, MD*
- Discussion: Head and Neck Cancer  
*Everett E. Vokes, MD*

**Session Title:** #83: Omics: Toward Personalizing Care

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- The genomics and genetics of melanoma  
*Kate Nathanson, MD, FACP*
- From high throughput transcriptomics to personalized cancer care  
*Dimitrios Spentzos, MD*
- Proteomics pathway analysis for tumor classification and therapy (focus on breast and ovary)  
*Gordon B. Mills, MD*

**Session Title:** #12: Angiogenesis: Where Do We Go from Here?

**Session Type:** Education Session

**Date:** Tuesday, June 8

- Genomic Approaches for Vascular Target Identification in Solid Tumors

*George Coukos, MD, PhD*

- Contrasting effects of VEGF pathway targeting antibodies and TKIs on microscopic versus advanced metastatic disease

*Robert S Kerbel, PhD*

- Targeting tumor angiogenesis - what have learned so far?

*Lee M Ellis, MD, FACS*